Helen Torley Sells 20,000 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $67.58, for a total value of $1,351,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $51,886,572.40. The trade was a 2.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

• On Wednesday, June 3rd, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $69.07, for a total value of $690,700.00.
• On Wednesday, May 13th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $69.19, for a total value of $691,900.00.
• On Tuesday, May 12th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $71.75, for a total value of $1,435,000.00.
• On Monday, April 6th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $63.50, for a total value of $635,000.00.
• On Thursday, April 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $64.24, for a total value of $1,284,800.00.

Halozyme Therapeutics Trading Up 2.5%

HALO opened at $71.60 on Friday. The stock has a market cap of $8.49 billion, a PE ratio of 25.76, a PEG ratio of 0.29 and a beta of 0.88. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. The business has a 50 day moving average of $66.63 and a 200-day moving average of $68.72. Halozyme Therapeutics, Inc. has a 52 week low of $51.06 and a 52 week high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. The company had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The firm’s revenue for the quarter was up 42.2% compared to the same quarter last year. During the same quarter last year, the business posted $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities research analysts predict that Halozyme Therapeutics, Inc. will post 7.61 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently commented on HALO shares. TD Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. HC Wainwright boosted their price target on Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Wells Fargo & Company boosted their price target on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 19th. Morgan Stanley dropped their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Finally, Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Eight research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $81.60.

Key Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks Research raised earnings forecasts for multiple future periods, including FY2026, FY2027, and FY2028, which strengthens the long-term growth story for Halozyme Therapeutics. Halozyme Therapeutics article
• Positive Sentiment: Analysts also increased estimates for several 2027 quarters, including Q1, Q2, Q3, and Q4, suggesting improving earnings momentum. Halozyme Therapeutics article
• Neutral Sentiment: Some near-term and farther-out estimates were mixed, with a slight cut to Q2 2026 and a reduction in Q1 2028, indicating the outlook improved overall but not across every period. Halozyme Therapeutics article
• Neutral Sentiment: Recent insider sales by the CEO and a director were disclosed, but both were made under pre-arranged 10b5-1 trading plans, which typically makes them less alarming to investors. Halozyme Therapeutics article

Hedge Funds Weigh In On Halozyme Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Measured Wealth Private Client Group LLC lifted its holdings in shares of Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 124 shares during the period. Larson Financial Group LLC lifted its holdings in shares of Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 343 shares during the period. Clearstead Advisors LLC lifted its holdings in shares of Halozyme Therapeutics by 107.7% during the 3rd quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 265 shares during the period. Harbour Investments Inc. lifted its holdings in shares of Halozyme Therapeutics by 152.5% during the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 372 shares during the period. Finally, Penserra Capital Management LLC bought a new position in shares of Halozyme Therapeutics during the 3rd quarter valued at $52,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.